[Cystic fibrosis. Current indications for nebulized treatments: antibiotics and DNase].
作者信息
Sardet-Frismand A
机构信息
CH Lens, Service de Pédiatrie.
出版信息
Rev Mal Respir. 1999 Jan;16 Suppl 3:S131-2.
PMID:10088286
Abstract
摘要
相似文献
1
[Cystic fibrosis. Current indications for nebulized treatments: antibiotics and DNase].[囊性纤维化。雾化治疗的当前适应证：抗生素和脱氧核糖核酸酶]
Rev Mal Respir. 1999 Jan;16 Suppl 3:S131-2.
2
Aerosolized deoxyribonuclease for cystic fibrosis.
Med Lett Drugs Ther. 1994 Apr 15;36(920):34-5.
3
Dornase alfa: a new option in the management of cystic fibrosis.多纳酶α：治疗囊性纤维化的新选择。
Pharmacotherapy. 1996 Jan-Feb;16(1):40-8.
4
What is the cystic fibrosis clinician supposed to do with human recombinant dornase alfa?
J Pediatr. 2001 Dec;139(6):768-70. doi: 10.1067/mpd.2001.120267.
5
[Current therapeutic agents: dornase alfa].
Rev Med Brux. 1997 Feb;18(1):37-40.
6
Nebulised bronchodilators, antibiotics and rhDNase for children with cystic fibrosis.用于囊性纤维化患儿的雾化支气管扩张剂、抗生素和重组人脱氧核糖核酸酶
Thorax. 1997 Apr;52 Suppl 2(Suppl 2):S89-91. doi: 10.1136/thx.52.2008.s89.
7
Dornase alfa therapy in cystic fibrosis: who should get it?
Chest. 1996 Oct;110(4):871-2. doi: 10.1378/chest.110.4.871.
8
Dornase alpha in the management of a mechanically ventilated infant with cystic fibrosis.
Pediatr Pulmonol. 1997 Aug;24(2):124-5.
9
[New pharmacological approaches: rhDNase].
Rev Pneumol Clin. 1995;51(3):193-200.
10
Primary ciliary dyskinesia: prospects for new therapies, building on the experience in cystic fibrosis.原发性纤毛运动障碍：基于囊性纤维化的经验探索新疗法的前景。
Paediatr Respir Rev. 2009 Jun;10(2):58-62. doi: 10.1016/j.prrv.2008.11.003. Epub 2009 Apr 9.
Zotero 插件